Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma.
Dario P AnobilePaolo BironzoFrancesca PiccaMarcello F LinguaDeborah MorenaLuisella RighiFrancesca NapoliMauro G PapottiAlessandra PittaroFederica Di NicolantonioChiara GigliottiFederico BussolinoValentina ComunanzaFrancesco GuerreraAlberto SandriFrancesco LeoRoberta LibenerPablo AvilesSilvia NovelloRiccardo TaulliGiorgio Vittorio ScagliottiChiara RigantiPublished in: Cancers (2021)
Overall, our data provide evidence that lurbinectedin exerts a potent antitumoral activity on primary MPM cells, independently from both the histological subtype and BAP1 alteration, suggesting its potential activity in the treatment of MPM patients.